Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.42 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.42 |
| ▸ | IGF2R | P11717 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CD209 | Q9NNX6 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21080980 | 0.91 | MAPK1 (0.40) | LGALS3MAPK1LGALS8LGALS4IGF2R | |
| SCHEMBL21080956 | 0.88 | MAPK1 (0.47) | LGALS3MAPK1LGALS8LGALS4IGF2R | |
| SCHEMBL30232030 | 0.88 | GAA (0.48) | LGALS3MAPK1LGALS8LGALS4L3MBTL1 | |
| SCHEMBL17339700 | 0.88 | GAA (0.48) | LGALS3MAPK1LGALS8LGALS4L3MBTL1 | |
| SCHEMBL24531345 | 0.88 | GAA (0.48) | LGALS3MAPK1LGALS8LGALS4L3MBTL1 | |
| SCHEMBL25484566 | 0.88 | GAA (0.48) | LGALS3MAPK1LGALS8LGALS4L3MBTL1 | |
| SCHEMBL17297124 | 0.88 | GAA (0.48) | LGALS3MAPK1LGALS8LGALS4L3MBTL1 | |
| SCHEMBL18769744 | 0.88 | GAA (0.48) | LGALS3MAPK1LGALS8LGALS4L3MBTL1 | |
| SCHEMBL21080979 | 0.86 | MAPK1 (0.54) | LGALS3MAPK1LGALS8LGALS4MEN1 | |
| SCHEMBL8160009 | 0.86 | GAA (0.49) | LGALS3MAPK1LGALS8LGALS4L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336966-B2 | Fragrance compositions and uses thereof | THE PROCTER & GAMBLE COMPANY (US) | 2019-07-02 | — | — | US | claimed |
| US-20210393506-A1 | FRAGRANCE BLENDS AND METHODS FOR PREPARATION THEREOF | JPMORGAN CHASE BANK, N.A. | 2021-12-23 | — | — | US | disclosed |
| WO-2020097181-A9 | FRAGRANCE BLENDS AND METHODS FOR PREPARATION THEREOF | COTY INC. (US) | 2021-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336966-B2 | Fragrance compositions and uses thereof | CUTA, DPM1, PLIN5 | LGALS3 3147/4885MAPK1 4405/4885LGALS8 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.